Search Results

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced follow-up data from its ongoing first-in-human Phase 1/2 trial (NCT04503278; 2019-004323-20) evaluating the safety and efficacy of the Company’s Claudin-6 (CLDN6)-directed CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors.

Iovance Biotherapeutics, Inc. announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share.

Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, announced that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology Annual Meeting, held in Chicago, June 2-6.

Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from human plasma for the prevention of FNAIT.

Agreement secures commerical supply of Astatine-211 to support the clinical development of PMI’s targeted alpha therapies.

The global Human Growth Hormone (hGH) market was estimated at USD 3,865.4 million in 2021 and it is expected to surpass around USD 9,211.73 million by 2030, poised to grow at a CAGR of 10.13% from 2022 to 2030.